Video Experimental Relacionado

Updated: May 2, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Los polimorfismos del receptor beta2-adrenérgico y el riesgo de eventos cardiovasculares incidentes en los ancianos

Susan R Heckbert¹, Lucia A Hindorff, Karen L Edwards

¹Department of Epidemiology, University of Washington, Seattle, USA. heckbert@u.washington.edu

|April 19, 2003

Resumen

La variante Glu27 del gen del receptor beta2-adrenérgico puede reducir el riesgo de eventos coronarios en adultos mayores. Este hallazgo se relaciona con las influencias genéticas en la salud cardiovascular y la respuesta simpática.

Área de la Ciencia:

La farmacogenómica es la farmacogenómica.
Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
Genética Humana Genética Humana.

Sus antecedentes:

Las variaciones genéticas en el receptor beta2-adrenérgico (ADRB2) en los codones 16 y 27 influyen en la respuesta del sistema nervioso simpático.
Estos polimorfismos se investigan por su papel potencial en el riesgo de enfermedad cardiovascular.

Objetivo del estudio:

Investigar la asociación entre los polimorfismos del gen ADRB2 (Arg16Gly y Gln27Glu) y el riesgo de eventos cardiovasculares.
Analizar estas asociaciones genéticas en el contexto del Estudio de Salud Cardiovascular.

Principales métodos:

Genotipización de polimorfismos de ADRB2 (Arg16Gly, Gln27Glu) en una cohorte de 808 participantes negros y 4441 blancos (edad media de 73 años).
Seguimiento prospectivo durante 7 a 10 años para determinar eventos coronarios incidentes, accidentes cerebrovasculares isquémicos y eventos cardiovasculares combinados.
Análisis estadístico utilizando ratios de riesgo e intervalos de confianza para evaluar las asociaciones genotipo-evento, estratificado por raza.

Principales resultados:

Las frecuencias alélicas para los polimorfismos de ADRB2 variaron significativamente según la raza, pero no según la edad o el estado de la hipertensión.
Los portadores del alelo Glu27 mostraron un riesgo reducido de eventos coronarios en comparación con los homocigotos de Gln27 (HR, 0.82; IC del 95%, 0.700.95).
Se observó una tendencia hacia una disminución del riesgo de eventos coronarios para los portadores de Gly16 frente a los homocigotos de Arg16 (HR, 0.88; IC del 95%, 0.721.07), aunque no fue estadísticamente significativa.

Conclusiones:

El alelo Glu27 del receptor beta2-adrenérgico está asociado con un menor riesgo de eventos coronarios incidentes en una población anciana.
Estos hallazgos sugieren un papel potencial para los genotipos específicos de ADRB2 en la modulación del riesgo cardiovascular en personas mayores.

Más Videos Relacionados

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Videos de Conceptos Relacionados

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...

Adrenergic Receptors: β Subtype

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...